01—Abstract
Summary
Summary of the 10-K filed March 3, 1994. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 1993 Form 10-K shows a company in strong form: net sales rose 7.1% to $8.41 billiona, and net earnings grew 12.9% to $1.40 billion, or $1.69 per share, up from $1.47 in 1992.
The improvement was helped by a $70 millionb pre-tax credit from resolving temafloxacin withdrawal contingencies, which offset a $104 million charge tied to infant formula antitrust settlements. Gross margin improved to 56.2% of sales, and operating earnings rose to $1.92 billion from $1.53 billion, partly because 1992 included a $215 million temafloxacin charge. Stronger U.S. dollar currency effects weighed on international sales, which were about 37% of worldwide sales.
Balance sheet and cash generation remained solid. Operating cash flow was $1.85 billionc, well above capital expenditures of $953 million and dividends paid of $548 million. Shareholders' investment reached $3.67 billion, and the company held AAA/Aa1 bond ratings.
Abbott issued $200 milliond of 5.6% notes due 2003 in October 1993 and repurchased roughly 49.6 million shares over three years. Total debt rose modestly, with long-term debt at $307 million and short-term borrowings at $842 million. The main investor risks are legal and regulatory.
Abbott faces seven infant formula antitrust suits and six investigations, 22 pharmaceutical pricing antitrust suits, 138 DES product liability cases, and Superfund remediation at eight sites. Management believes none should have a material adverse effect on financial position. Growth drivers include Biaxin, Similac, and the Lupron franchise, along with the health care reform debate and pending FDA device regulation that could raise compliance costs.
02—Key points
Key Highlights
- Net sales grew 7.1% to $8.41 billion in 1993, driven by 8.6% unit growth, partly offset by a 2.4% currency headwind from the stronger U.S. dollar.
- Net earnings rose 12.9% to $1.40 billion ($1.69 per share), supported by a $70 million pre-tax temafloxacin credit and a 28.0% effective tax rate.
- Gross profit margin improved to 56.2% from 55.4%, reflecting productivity gains and favorable product mix despite WIC rebate pressure on infant formula.
- R&D spending reached $881 million (10.5% of sales), with Abbott holding the leading worldwide erythromycin position and Similac as the top U.S. infant formula.
- Operating cash flow of $1.85 billion comfortably funded $953 million in capital expenditures and $548 million in dividends.
- Abbott maintained AAA (S&P) and Aa1 (Moody's) ratings, issuing $200 million of 5.6% notes due 2003 and repurchasing about 49.6 million shares over three years.
- Significant legal exposure remains, including infant formula and pharmaceutical antitrust suits, DES product liability claims, and Superfund cleanup obligations, which management does not expect to be materially adverse.
03—Questions
Frequently Asked Questions
How did Abbott's 1993 earnings compare with 1992, and what affected the comparison?
Net earnings were $1.40 billion, or $1.69 per share, up from $1.24 billion, or $1.47 per share, in 1992. 1992 was depressed by a $215 million pre-tax temafloxacin withdrawal charge, while 1993 benefited from a $70 million credit from resolving those contingencies. 1993 was also hurt by a $104 million infant formula settlement charge. 1992 included a $272 million pre-tax gain on the Boston Scientific stake sale, so the year-over-year comparison is distorted by these one-time items.
What are the main product franchises driving Abbott's sales?
Abbott reported three product classes contributing at least 10% of sales: Infant Formula ($1.15 billion), Medical Nutritionals ($864 million), and Fluids and Equipment ($836 million, which declined due to a product line sale). The pharmaceutical and nutritional segment grew 9.0% to $4.39 billion, while hospital and laboratory products grew 5.0% to $4.02 billion. Key drugs include Biaxin, Erythromycin, Depakote, and Lupron, with Lupron marketed through TAP Pharmaceuticals, a 50/50 joint venture with Takeda.
What are the biggest legal and regulatory risks disclosed?
The most significant exposures are seven infant formula antitrust suits and six investigations, which allege price-fixing and bid-rigging related to WIC contracts, 22 pharmaceutical pricing antitrust suits, and 138 DES-related product liability cases. Abbott is also a potentially responsible party at eight Superfund sites. Management says the ultimate outcomes should not have a material adverse effect on financial position, but it acknowledges that the Superfund cost estimates could reach several hundred million dollars in aggregate across all parties. Broader risks include U.S. health care reform, expanded FDA user fees for medical devices, and tighter device regulation.
How strong is Abbott's balance sheet and financial flexibility?
Shareholders' investment was $3.67 billion at year-end 1993, up from $3.35 billion. Total assets were $7.69 billion. Long-term debt was $307 million after the $200 million notes issuance, and short-term borrowings were $842 million, mostly commercial paper. The company held $300 million of unused domestic credit lines and was rated AAA by S&P and Aa1 by Moody's. Operating cash flow of $1.85 billion comfortably covered capital spending and dividends, and the company retained authority to issue up to $300 million of additional debt securities under its shelf registration.
What are the company's capital allocation priorities?
Capital expenditures were $953 million in 1993, roughly flat with 1992, and management expects this spending level to continue, split roughly equally between the pharmaceutical and hospital segments. Dividends were $0.68 per share, up from $0.60, and total cash dividends paid reached $548 million. Abbott repurchased about 49.6 million shares over the last three years for $1.39 billion, including 5.9 million shares under the September 1993 authorization of 20 million shares. R&D was $881 million, focused on diagnostics and pharmaceuticals.
04—Continue